Sign in
NCNA Stock Price, Chart, Stats & News
NuCana plc
Save
11.60M
Market cap
0.01x
Current P/E
–
Forward P/E
NCNA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 3.83% |
ROA | -98.45% |
ROE | -189.88% |
D/E | 0.03x |
Interest coverage ratio | – |
NCNA valuation
P/E | 0.01x |
P/S | – |
P/B | 0.16x |
P/CF | -0.54x |
P/FCF | -0.87x |
P/OCF | -0.54x |
PEG | 0.02x |
EV multiple | -1.46x |
About
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer.
Similar securities
Based on sector and market capitalization
Report issue